Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 15INDUSTRY 4NIH 2NETWORK 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Endometrial Adenocarcinoma 1Advanced, Persistent, or Recurrent Endometrial Cancer 1

Interventions

Radiotherapy 302Cisplatin 266Cyclophosphamide 230Doxorubicin 177Paclitaxel 170Vincristine 162Carboplatin 152Filgrastim 140Etoposide 139Gemcitabine 118Docetaxel 114Fluorouracil 113Methotrexate 106Dexamethasone 106Cytarabine 106Prednisone 92Leucovorin 90Gene Expression Profiling 82Granulocyte Colony-Stimulating Factor 75Specimen Handling 70Magnetic Resonance Spectroscopy 63Irinotecan 59Capecitabine 59Radiation 54Polymerase Chain Reaction 51Ifosfamide 51Rituximab 49Immunohistochemistry 49Daunorubicin 49Oxaliplatin 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Medroxyprogesterone Acetate × Clear all
NCT02228681 2024-09-19

Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer

GOG Foundation

Phase 2 Completed
74 enrolled 13 charts
Gynecologic

Advanced, Persistent, or Recurrent Endometrial Cancer

NCT00064025 2016-04-11

Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus

GOG Foundation

Phase 2 Completed
75 enrolled 6 charts
Gynecologic

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡